Variation in Gamma-Globin Expression before and after Induction with Hydroxyurea Associated with BCL11A, KLF1 and TAL1

Amanda J. Grieco1, Henny H. Billett2, Nancy S. Green3, M. Catherine Driscoll4, Eric E. Bouhassira1*

1 Department of Cell Biology, Albert Einstein College of Medicine, Bronx, New York, United States of America, 2 Division of Hematology, Department of Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, United States of America, 3 Division of Pediatric Hematology/Oncology/Stem Cell Transplantation, Department of Pediatrics, Columbia University, New York, New York, United States of America, 4 Department of Pediatrics, Division of Hematology-Oncology, AECOM, Bronx, New York, United States of America

* eric.bouhassira@einstein.yu.edu

Abstract

The molecular mechanisms governing γ-globin expression in a subset of fetal hemoglobin (α2γ2: HbF) expressing red blood cells (F-cells) and the mechanisms underlying the variability of response to hydroxyurea induced γ-globin expression in the treatment of sickle cell disease are not completely understood. Here we analyzed intra-person clonal populations of basophilic erythroblasts (baso-Es) derived from bone marrow common myeloid progenitors in serum free cultures and report the level of fetal hemoglobin production in F-cells negatively correlates with expression of BCL11A, KLF1 and TAL1. We then examined the effects of hydroxyurea on these three transcription factors and conclude that a successful induction of γ-globin includes a reduction in BCL11A, KLF1 and TAL1 expression. These data suggests that expression changes in this transcription factor network modulate γ-globin expression in F-cells during steady state erythropoiesis and after induction with hydroxyurea.

Introduction

Understanding the mechanisms which govern γ-globin expression in adult erythropoiesis is important for developing therapeutic targets for the β-hemoglobinopathies [1]. In sickle cell disease, induction of γ-globin expression decreases the formation of sickle polymers in red blood cells under de-oxygenation conditions. An increase in fetal hemoglobin (α2γ2: HbF) to a threshold level of 20% has been associated with a more benign disease course [2, 3].

Hydroxyurea (HU) was the first drug approved by the FDA for clinical use in sickle cell patients to induce HbF [4] after its clinical effectiveness in reducing acute disease complications of painful crises and hospitalizations was demonstrated [5, 6]. The ameliorative effects of HU on sickle cell disease also include improved blood flow in the microcirculation and a decreased
transfusion requirement [7]. However, clinical and laboratory response to HU is highly variable [8, 9]. Most specifically, not all patients reach a clinically significant increase in HbF even at maximum tolerated dose [10, 11]. Differences in baseline HbF levels and DNA polymorphisms, including a SNP in the BCL11A gene, have been investigated as predictors of response to HU among patients [11–13]. However, no predictor alone or in combination has been able to fully predict HbF induction levels after HU treatment signifying the involvement of other uncharacterized factors [11, 12, 14].

The molecular mechanism of action of HU on γ-globin induction remains elusive, despite the clinical significance for treatment of sickle cell disease and other β-hemoglobinopathies [15]. Largely, expression studies of the effect of HU in erythroid cells have revealed changes in miRNAs and gene groups involved in metabolism, translation, cell cycle and RBC cytoskeleton [9, 16–20]. Only recently have two transcription factors, BCL11A and SOX6, been shown to decrease in response to HU in vivo in sickle cell reticulocytes [18]. By contrast, studies with erythroid progenitors derived in vitro from PBMCs of hydroxyurea responsive and non-responsive β-thalassemia patients have shown SOX6 expression is high in responders in the presence of HU [19] while BCL11A remained unchanged between patients. These conflicting results may reflect underlying differences in globin transcription factor networks between the two diseases or differences between the types of erythroid progenitors tested.

BCL11A was discovered through genome-wide association studies to be a powerful modulator of human HbF levels in non-anemic individuals [21–23]. This zinc finger protein has subsequently been shown to bind several regions at the β-globin locus including the locus control region (LCR), a cis-regulatory element involved in long-range interactions with β-like genes to modulate globin expression. Together with several other transcription factors, BCL11A coordinates the repression of γ-globin during definitive erythropoiesis [24–26]. At the proximal promoter of the γ-globin gene in human erythroid cells, BCL11A and SOX6 have been demonstrated to bind cooperatively and facilitate contact with the LCR in favor of silencing γ-globin expression [26].

KLF1 has been shown to directly regulate BCL11A expression [27] and is an essential activator of β-globin expression [28, 29] thought to play a central role in stabilizing long range binding between the promoter of the β-globin gene and the LCR in adult erythroid cells [30]. Individuals with haplo-insufficiency for KLF1 show increased levels of HbF [31].

TAL1 is a core erythroid transcription factor which assembles with GATA1, LMO2 and LDB1 in a multimeric protein complex during erythroid maturation [32–35]. This complex induces globin gene expression by facilitating direct contact between the locus control region and the globin gene promoters via chromatin looping [34, 36, 37].

Expression of HbF in normal adult blood is generally below 1% of total hemoglobin and occurs in a fraction of red blood cells termed F-cells [38, 39]. The origin of these F-cells and determination of cellular heterogeneity in globin gene expression within the same individual are not well understood as erythroblast progeny of the same BFU-E can express variable levels of γ-globin demonstrating clonal variability [40]. Changes in the epigenetic program in erythroid progenitors during definitive erythropoiesis may determine γ-globin expression in the more mature progeny, and a class of early precursors may exist that can produce descendant stem cells with or without commitment to HbF production. Whether the same transcription factors are involved in generating cellular heterogeneity in globin gene expression within the same individual during steady state erythropoiesis, after HU induction and in the variation of HbF expression between individuals is not fully characterized.

Using an approach based on the analysis of clonal populations of basophilic erythroblasts (baso-Es) derived in serum free culture of bone marrow (BM) common myeloid progenitors (CMP), we report here that the level of HbF production in baso-Es is not yet determined at the
CMP level since sub-cultures of daughter cells derived from the same CMPs exhibit different levels of γ-globin expression. We also show that the variations in HbF levels in normal basophilic erythroblasts negatively correlates with expression of BCL11A, KLF1 and TAL1 and that the same genes are further down-regulated after successful induction with HU.

Material and Methods

Primary Sample Sources

10mL of peripheral blood was obtained from an equal number of male and female sickle cell patients ranging in age from 11–52 years old from a diversity of ethnic backgrounds with a confirmed diagnosis of HbSS. This study was approved by the Albert Einstein College of Medicine Internal Review Board (CCI protocol #2008–201). Written and signed informed consent was obtained from patients or their guardians. Control peripheral blood samples were provided as discarded whole blood units from the New York Blood Center (New York, NY). Peripheral blood mononuclear cells were isolated with Histopaque-1077 (Sigma-Aldrich; St. Louis, MO, USA) following vendor’s protocol. CD34⁺ cells were isolated using the Positive Selection EasySep Human CD34⁺ Selection Kit according to vendor’s protocol (StemCell Technologies; Vancouver, BC, Canada) Bone marrow aspirates enriched for CD34⁺ were commercially obtained (StemCell Technologies) from eight unrelated, healthy female donors of different ethnic backgrounds. Donors with a self-reported history of hematologic disease or disorders were excluded.

Cell Lines

AFT024 mouse fetal liver [41] cell line was obtained from ATCC and grown according to ATCC recommendations. When confluent, cells were irradiated at 12000rad and plated to be 90% confluent on 0.1% gelatinized plates. Plates were incubated at 37°C overnight before adding progenitor cells.

Isolation of Common Myeloid Progenitors from Bone Marrow

CD34⁺ enriched cells from bone marrow mononuclear cells were stained with monoclonal human specific antibodies for phycoerythrin (PE)-Cy5-conjugated lineage markers: CD2 (RPA-2.10), CD3(UCHT2), CD10(CB-CALLA), CD19(SJ25-C1), CD20(2H7) (e-bioscience; San Diego, CA; USA); CD4(S3.5), CD7(6b7), CD8(3B5), CD14(TUK4), CD15(MEM-188), CD235a(CLB-ery-1(AME-1) (Life Technologies; Grand Island, NY, USA) and human specific antibodies CD34-APC(581/CD34 class III epitope) and CD123-PE(6H6) (BD Bioscience, San Jose, CA; USA); CD38- PE-Cy7(HIT-2) (e-bioscience); CD45RA- FITC(MEM-56) (Life Technologies) were used to isolate Common Myeloid Progenitor cells (Lin⁻, CD34⁺, CD38⁺, CD45RA⁻, CD123low) (adapted from [42]. CMPs were directly sorted as single cells into 96-well round tissue culture treated plates (BD Biosciences) prepared with irradiated AFT024 cells as described above. Cells were sorted on FACSAria (BD Biosciences) using FACSDiva software (BD Biosciences). Compensations were adjusted with the use of beads (Life Technologies) and unstained CD34⁺ bone marrow was used as negative controls to establish gating strategy (Invitrogen; Carlsbad, CA, USA).

Growth Conditions

Single cell common myeloid progenitors were grown in erythrocyte expansion and differentiation culture conditions adapted from [43]. Briefly, serum-free basal media StemSpan SFEM (Stem Cell Technologies) with 1% Penicillin-Streptomycin was supplemented with a two-phase
cytokine cocktail. In the first 7 days, 10^{-6} M hydrocortisone (Sigma-Aldrich), 13 ng/mL IL3 (PeproTech; Rocky Hill, NJ; USA), 13 ng/mL BMP4 (R&D Systems, Inc.; Minneapolis, MN; USA), 33 ng/mL FLT3L (Prospect; East Brunswick, NJ, USA), 100 ng/mL SCF (Prospect), and 2.7 U/mL EPO (Amgen; Thousand Oaks, CA, USA) supplemented the media. In the second phase, 10^{-6} M hydrocortisone (Sigma-Aldrich), 13 ng/mL IL3 (PeproTech), 13 ng/mL BMP4 (R&D Systems, Inc.), 40 ng/mL SCF (Prospect), 3.3 U/mL EPO (Amgen) and 40 ng/mL IGF1 (Biomedical Technologies; Ward Hill, MA, USA) supplemented the media for the next 7 days. Media was refreshed every 3–4 days in both phases. At day 14, when cells reached the basophilic erythroblast stage of differentiation, experiments were terminated and RNA or protein collected. A constant dose of 15 μmol/liter of HU (Sigma-Aldrich) was titrated in serum-free conditions to achieve a modest HbF increase with admissible cellular viability for downstream analysis. This concentration was maintained throughout the experiment starting from day 4 of single cell experiments. Erythroid developmental stage was confirmed by CD235a and CD71 expression.

Analysis of Globin Expression

Protein levels were assessed using reverse phase High Performance Liquid Chromatography with Vydc/Grace C4 or Proto300 C4 columns optimized for hemoglobin using a linear gradient of acetonitrile with trifluoroacetic acid. Samples were prepared as described [44]. Briefly, collected cells were washed three times with calcium/magnesium free PBS and lysed in water by 3 freeze-thaw cycles between liquid nitrogen and 37°C water bath. Percent γ-globin was calculated as a ratio of γ-globin to all β-like globins 100/(Gγ + Aγ)/(β + Gγ + Aγ). Globin expression was analyzed by quantitative real-time (qRT) PCR. Total RNA from cells was extracted using RNeasy Kits (QIAGEN; Valencia, CA, USA) and cDNA synthesized using SuperScript II First-Strand Synthesis System (Life Technologies). qRT-PCR was performed with a one-step SYBR-Green RT-PCR kit (QIAGEN). Primers used were designed in PearlPrimer (Owen Marshall) or with the help of PrimerBank [45]. Primer sequences listed (S1 Fig).

All PCR reactions were performed in triplicates. Result were normalized to GAPDH expression using the ΔCts methods. All qRT-PCR reaction (reverse transcription and PCR reaction) were repeated at least three times on three different days.

The % γ-globin expression was calculated as

\[ \frac{100}{1 + \left(1/\text{(fold difference } \gamma/\text{fold difference } \beta)\right)} \]

Fold differences relative to GAPDH were calculated as \(2^{\Delta\text{Ct}}\).

Threshold cutoffs for low vs high γ-globin expressing baso-E progeny were below 20% and above 70% γ-globin respectively.

Analysis Software/Statistical Programs

Statistical significance determined by GraphPad Prism 6.0 (GraphPad Software Inc; La Jolla, CA, USA). Statistically significant results were based on triplicate independent qRT-PCRs with a standard deviation less than 0.5 of triplicates per individual plate. The unpaired Student’s t-test was utilized with statistically significant P values <0.05.

Results

γ-globin expression is highly variable between progenitor populations and donors

Variation in endogenous γ-globin expression has been associated with several polymorphisms that result in inter-person heterogeneity of HbF before and after treatment with HU [11, 12].
We hypothesized that a serum-free, multi-phase liquid culture experimental system previously defined by our lab and others to enhance adult erythropoiesis could be adapted to preserve this heterogeneity in vitro in primary cells isolated from unrelated and ethnically diverse blood donors. The culture system allows for the expansion and differentiation of CD34+ hematopoietic progenitors into baso-Es in 14 days [43]. At this developmental stage, high-performance liquid chromatography (HPLC) can be performed to analyze globin expression. We show that peripheral blood mononuclear cells (PBMCs) isolated from both non-sickle and sickle cell donors produce baso-Es populations that preserve inter-donor heterogeneity in HbF levels (Fig 1A and 1B).

In an effort to mimic physiologic baseline $\gamma$-globin expression, we modified our culture system by co-culturing the cells on AFT024 mouse embryonic liver stromal cells [41] because it was recently demonstrated that erythroid progenitors derived from baboon BM co-cultured with AFT024 express $\gamma$-globin close to physiologic levels [46]. HPLC analysis of baso-Es derived from human BM produced in these in vitro conditions express a level of $\gamma$-globin nearly equivalent to physiologic expression in contrast to the control without co-culture (Fig 1C and 1D).

Variation in HbF levels observed in biological replicate experiments with small numbers of seed cells prompted us to further refine the culture system. We aimed to (1) standardize the differentiation stage of our starting progenitor population isolated from donor samples to control for HbF variations which might arise from kinetic changes in steady-state hematopoiesis in the donors [47]; and (2) perform experiments on clonally derived cell populations to reveal differences in HbF potential among intra-donor progenitor populations [38].

To accomplish these aims, CMPs expressing a committed lineage-/CD34+/CD38+/CD123low/CD45RA- marker phenotype from healthy bone marrow (BM) donors were sorted directly into 96-well plates at a concentration of one cell per well. After 14 days of culture, the baso-E clones derived from the single cells were collected, RNA was extracted and qRT-PCRs were performed to examine $\gamma$-globin expression which reliably correlates to HbF expression [14]. Clonal baso-Es derived from single CMPs showed an intra-donor $\gamma$-globin heterogeneity which is preserved even after background $\gamma$-globin adjustments with the use of AFT024 co-cultures (Fig 1D). Expression of $\gamma$-globin ranged from about 30 to 65% (average = 49.4% +/- 4.02(SD)) and from 5% to 38% (average = 17.97% +/- 2.44 (SD)) in AFT024- and AFT024+ conditions respectively.

Characterization of $\gamma$-globin expression variability in clonal sibling baso-E populations

In an attempt to prospectively isolate hematopoietic progenitors already committed to either a high or low $\gamma$-globin expression program in their more mature progeny, we performed experiments where daughter cells of single BM CMPs were divided into two separate sister wells and allowed to differentiate in parallel for 10 days prior to hemoglobin analysis by qRT-PCR (Fig 2A). The level of $\gamma$-globin expression in the sister cultures varied between 5% and 60%. We found that baso-Es expressed significantly different amounts of $\gamma$-globin in 5 out 14 sister clonal culture tested (Fig 2B) suggesting that the epigenetic programs for globin gene expression is not defined at the CMP stage of differentiation in control individuals.

$\gamma$-globin expression in response to HU in clonal cultures of baso-Es generated from BM CMPs is variable

To characterize the response to HU in our clonal progeny assay in a genetically controlled intra-donor setting, we FACS sorted single BM CMPs and added HU to half the wells. $\gamma$-globin
Fig 1. Inter and intra-individual variation in γ-globin expression in baso-Es produced in the presence or absence of AFT024. (A) Variation in HbF levels are recapitulated in culture. Peripheral blood mononuclear cells (PBMCs) from four control donors (left panel) and four sickle cell donors (right panel) were differentiated in vitro into populations of baso-Es and globin expression was determined by HPLC. Baso-Es were collected on day 14 of culture system. Percent γ-globin was calculated as \( \frac{(100 \times (G_\gamma + A_\gamma))}{(G_\gamma + A_\gamma + \beta)} \). Error bars represent standard deviation in γ-globin levels over independent biological replicates. (B) Co-culture of CD34+ cells with AFT024 stromal cells decrease background γ-globin expression. CD34+ PBMCs from two control donors were isolated, split into two fractions and differentiated into baso-Es in vitro in the presence or absence of mouse embryonic liver stromal cells (AFT024). On day 14, baso-Es were collected for HPLC analysis. Representative chromatograms of globin expression obtained by HPLC analysis from circulating red blood cells in vivo (left chromatograms), day 14 baso-Es populations derived in vitro from CD34+ PBMCs without AFT024 stromal cell co-culture (middle chromatogram) or with AFT024 co-culture (right chromatogram). (C) Histogram illustrating the HPLC quantification of the effect of AFT024 on γ-globin expression. Average percent γ-globin shown, error bars represent percent γ-globin variation between donors. (D) Clonal population of baso-E exhibit large variation in γ-globin expression. Individual Common Myeloid Progenitors (CMPs) were isolated from a control bone marrow (BM) donor and placed in culture with or without AFT024 cells to generate clonal populations of baso-Es. After 14 days of culture, the percent of γ-globin expression \( (\gamma/\gamma + \beta) \) was determined by qRT-PCR analysis. Error bars represent the standard deviation in average γ-globin expression between replicate rounds of qRT-PCR.

doi:10.1371/journal.pone.0129431.g001
expression of baso-E clones demonstrated, similar to baseline studies, that an inter-donor and intra-donor heterogeneity exists (Fig 3A). To assess inter-donor response to HU, clones from the same donors were pooled into their dose respective groups and average expression of γ-globin in the presence or absence of induction with HU was compared (Fig 3B). To determine if HU affected the kinetics of erythroblast maturation in our cultured cell system, we compared expression of CD235a and CD71 between baseline and HU conditions. No statistically significant differences were found (Fig 3C).

To further explore the gene program differences in intra-donor clones that might explain variation in baseline γ-globin expression level, qRT-PCR was performed on candidate genes that have previously been implicated in the regulation of erythropoiesis and globin expression. Analysis of 10 to 15 clonal cultures with a panel of PCR primers including BCL11A, KLF1, TAL1, GATA1, GATA2, SOX6, CD71 and CD235a revealed statistically significant reduced levels in expression in the high γ-globin cultures compared to the low γ-globin cultures for only three genes: BCL11A, KLF1 and TAL1 (Fig 4A and S2 Fig). The average fold differences
in gene expression relative to GAPDH ($2^{\Delta\Delta Ct}$) in the low γ-globin clones were -23.6 +/- 5.0 (mean +/- standard error) for BCL11A, -3.9 +/- 0.6 for KLF1, and -13.7 +/- 3.4 for TAL1. In the high γ-globin clones, the average fold differences were -48.6 +/- 11.7 for BCL11A, -31.5 +/- 9.1 for KLF1 and -36.6 +/- 3.6 for TAL1.
To determine the changes in expression of these specific transcription factors with HU mediated induction of γ-globin, we performed qRT-PCR on clonal cultures derived from two healthy bone marrow donors. We found these donors differed in their response to HU in vitro. Donor 1 responded with a statistically significant increase in γ-globin and significant decreases in BCL11A, TAL1 and KLF1. In comparison, donor 2 failed to significantly respond to induction of γ-globin and also failed to reach statistically significant decreases in expression of all three genes (Fig 4B). The average fold differences in gene expression relative to GAPDH ($2^{-\Delta\Delta Ct}$) in donor 1 baseline clonal populations were -27.91 +/- 4.7 for BCL11A, -6.7 +/- 2.0 for KLF1 and -21.0 +/- 2.6 for TAL1; and the average fold differences in the presence of HU were -197.1 +/- 43.3 for BCL11A, -14.09 +/- 1.7 for KLF1, and -68.8 +/- 9.9 for TAL1.

Other candidate genes tested revealed that response to HU induction was also associated with decreased expression of SOX6 (Fig 5). GATA1, GATA2, CD235a and CD71 expression

Fig 4. Gene expression analysis in intra-donor unicellular BM CMP derived baso-E progeny. (A) Intra-donor clonal cultures of baso-Es generated in the presence of AFT024 were assigned into groups based on low and high levels of γ-globin expression. qRT-PCRs for select genes were performed. Histograms represent the average fold differences in gene expression relative to GAPDH calculated as $2^{-\Delta\Delta Ct}$. Error bars represent the standard error of the mean between independent clones pooled into expression group. Statistical significance was determined using student’s t-test with significant values p<0.05 denoted. (B) Clonal cultures of baso-Es from two non-sickle donors (donor 1 and 2 from Fig 3) were co-cultured on AFT024 with or without 15μM HU. qRT-PCRs for select genes were performed on individual clones in triplicate. Fold differences relative to GAPDH calculated as above. Histograms represent the average expression of the pooled clones and error bars represent the standard error between individual clones in dose status group. Statistical significance determined as above.

doi:10.1371/journal.pone.0129431.g004


Discussion

Using baso-Es derived in vitro from CD34+ cells enriched from unrelated, healthy human bone marrow donors, we found that clonal cultures derived from individual CMPs expressed considerable heterogeneity in the level of expression of HbF, even when daughter cells derived from a single CMP were cultured and analyzed in parallel. This finding suggests that the level of γ-globin expression in baso-Es may be determined late during the differentiation process and that a single CMP can give rise to baso-Es that express either low or high γ-globin levels. Q-RT-PCR analysis of multiple baso-E clones derived from the same donor revealed that high levels of γ-globin expression were associated with decreased expression of the major transcriptional regulators BCL11A, KLF1 and TAL1.

The mechanisms that control the level of expression of these three transcription factors in individual baso-Es and that ultimately determine the levels of HbF expression are still under investigation. Our culture system is highly standardized, serum-free and includes only recombinant cytokines. Therefore, it seems unlikely that the variations in γ-globin expression are caused by changes in the environment, particularly because the variations in globin expression were observed in multiple independent experiments using multiple donors (Fig 1). Additionally, similar levels of CD71 and CD235a among the clones indicate that the differences in gene programs observed cannot be explained by differences in maturation levels of the baso-Es because they are at similar stages of differentiation. The most likely explanation is that expression of the β- and γ-globin genes is inherently unstable and that stochastic processes controlling the levels of expression of BCL11A, KLF1 and TAL1 late in erythroid differentiation determine whether β- or γ-globin will be predominantly expressed.

Comparison of clonal cultures derived from individual CMPs grown in the presence or absence of HU revealed that a decrease in expression of the three transcription factors BCL11A, KLF1 and TAL1 is also associated with higher levels of γ-globin expression. This observation indicate no statistically significant differences in expression between baseline and HU conditions in either the responding or non-responding donor (Fig 5).

**Fig 5. Expression of candidate genes in clonal populations of baso-Es in the presence or absence of HU.**

Clonal cultures of BM CMP derived baso-Es from two non-sickle donors (donor 1 and 2 from Fig 3) co-cultured on AFT024 with or without 15μM HU. qRT-PCRs for candidate genes were performed in triplicate. Fold differences relative to GAPDH were calculated as 2^(-ΔΔCt). Histograms represent the average expression of the pooled clones and error bars represent the standard error between individual clones in dose status group.

doi:10.1371/journal.pone.0129431.g005
suggests that the same transcription factor networks responsible for high γ-globin expression in a subset of normal baso-Es play a role in induction of γ-globin by HU. This conclusion is supported by the observation in donor 2 where failure to respond to HU was associated with a lack of expression change in these factors.

Since lack of CD71 and CD235a expression changes with HU indicate the kinetics of erythroid differentiation was not markedly altered with the addition of HU (Fig 5), it is likely that HU acts by resetting the basal program of expression for these three factors (BCL11A, KLF1, TAL1) to a lower level. Lowering basal expression would increase the likelihood of γ-globin expression but continue to preserve the γ-globin variability that we observed among individual baso-Es grown in the absence of this drug (S2 Fig). Clinical response to HU may, therefore, depend on resetting the basal expression of these factors to levels low enough to favor γ-globin expression over β-globin in a critical number of cells and may explain why gene expression studies on total populations of erythroid cells have yet to implicate all three factors in the HU response.

Several known interactions between TAL1, KLF1, BCL11A can help explain, in molecular terms, the high γ-globin expression in baso-Es that occurs spontaneously or after induction by HU.

The first interaction is through BCL11A which negatively regulates γ-globin expression. TAL1 has recently been shown to bind to an intronic enhancer in BCL11A [48]. Bauer et al have shown that lower binding of TAL1 at this site in the presence of the minor T allele was associated with lower BCL11A and high HbF expression suggesting that TAL1 might negatively regulate HbF by positively regulating BCL11A.

The second interaction is through TAL1 and the LCR. TAL1 is a DNA-binding component of the pentameric LDB1 complex and has been shown to be indispensable to long range interactions between the LCR and globin genes in K562 cells [49]. Decreased expression of TAL1 might therefore interrupt looping of the LCR to the β-globin promoter causing a decrease in its expression and providing a competitive advantage for other complexes to induce γ-globin expression.

The third interaction is through KLF1, a known inducer of BCL11A [27, 31]. Two lines of evidence suggest that TAL1 might regulate KLF1 both directly and indirectly. TAL1 has been shown to bind to the KLF1 promoter (ENCODE consortium) and to the intergenic enhancer binding site of the MYB gene, itself an activator of KLF1 [50, 51]. A 3bp indel in the regulatory region of MYB alters the spatial configuration of the TAL1/GATA1 enhancer binding site and results in a decrease in MYB expression associated with high HbF [52] suggesting TAL1 may indirectly regulate KLF1 through this mechanism.

Taken together, these observations suggest that in low HbF cells, γ-globin expression is low because BCL11A expression is high because TAL1 and KLF1 are high. High levels of BCL11A and TAL1 favor looping of the LCR to the β-globin gene promoter enhancing its expression. [26, 34]

In high HbF cells, BCL11A is low because TAL1 and KLF1 are low and the γ-globin gene promoters can compete for contact with the LCR.

In the presence of HU, we observe that the same transcription factor network is involved with γ-globin induction along with a decrease in SOX6 expression suggesting the β-globin locus chromatin has been configured to favor γ-globin expression [26]. This decrease in SOX6 expression supports the findings by Flanagan et al in sickle cell patients but is in opposition to Pourfarzad et al results in β-thalassemia patients. Experiments to confirm our results in sickle cell baso-Es remain to be performed but are encourage by corroboration of SOX6 and BCL11A data with Flanagan et al.
The major conclusions of these studies is that production of baso-Es that express high HbF, both spontaneously in healthy individuals during steady state erythropoiesis and after induction with HU, is controlled by the same three transcription factors BCL11A, KLF1 and TAL1. It is unclear how HU controls expression of these three factors and of SOX6. Whether expression of these factors during late erythroid differentiation or after induction with HU is controlled by a single gene or by meta-stable erythroid networks differing by the expression of many genes established in a stochastic manner requires additional research.

Supporting Information
S1 Fig. Primer Sequences. (TIF)

S2 Fig. Expression of candidate genes in clonal populations of baso-Es as a function of γ-globin expression. (TIF)

Acknowledgments
We thank the sickle cell patients and families for their participation in these studies. We are indebted to Lisa Sarran-Armogan, Sandra M. Suzuka, and Guillermo Simkin for outstanding technical teaching and assistance.

Author Contributions
Conceived and designed the experiments: AJG HHB EEB. Performed the experiments: AJG. Analyzed the data: AJG EEB. Contributed reagents/materials/analysis tools: HHB NSG MCD EEB. Wrote the paper: AJG NSG EEB.

References
1. Pace BS, Zein S. Understanding mechanisms of gamma-globin gene regulation to develop strategies for pharmacological fetal hemoglobin induction. Dev Dyn. 2006 Jul; 235(7):1727–37. PMID: 16607652
2. Noguchi CT, Rodgers GP, Serjeant G, Schechter AN. Levels of Fetal Hemoglobin Necessary for Treatment of Sickle Cell Disease. N Engl J Med. 1988; 318(2):96–9. PMID: 2447498
3. Powars D, Weiss J, Chan L, Schroeder W. Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia? Blood. 1984; 63(4):921–6. PMID: 6200161
4. Platt OS, Orkin SH, Dover G, Beardsley GP, Miller B, Nathan DG. Hydroxyurea Enhances Fetal Hemoglobin Production in Sickle Cell Anemia. J Clin Invest. 1984; 74:652–6. PMID: 6205021
5. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert S V., et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995; 332(20).
6. Lanzkron S, Strouse JJ, Wilson R, Beach MC, Haywood C, Park H, et al. Systematic Review: Hydroxyurea for the Treatment of Adults with Sickle Cell Disease. Ann Intern Med. 2008; 148:939–55. PMID: 18458272
7. Wang WC, Ware RE, Miller ST, Iyer R V, Casella JF, Minniti CP, et al. A multicenter randomised controlled trial of hydroxyurea (hydroxycarbamide) in very young children with sickle cell disease. Lancet. 2011; 377(9778):1663–72. doi: 10.1016/S0140-6736(11)60355-3 PMID: 21571150
8. Green NS, Ender KL, Pashankar F, Driscoll C, Giardina PJ, Mullen CA, et al. Candidate sequence variants and fetal hemoglobin in children with sickle cell disease treated with hydroxyurea. PLoS One. 2013 Jan; 8(2):e55709. doi: 10.1371/journal.pone.0055709 PMID: 23409025
9. Walker AL, Steward S, Howard T a, Mortier N, Smeltzer M, Wang Y-D, et al. Epigenetic and molecular profiles of erythroid cells after hydroxyurea treatment in sickle cell anemia. Blood. 2011 Nov 17; 118(20):5664–70. doi: 10.1182/blood-2011-07-368746 PMID: 21921042
10. Steinberg MH, Lu Z, Barton FB, Terrin ML, Charache S, Steinberg GJ. Fetal Hemoglobin in Sickle Cell Anemia: Determinants of Response to Hydroxyurea. Blood. 1997; 89(3):1078–88. PMID: 9028341
11. Ware RE, Despotovic JM, Mortier N a, Flanagan JM, He J, Smeltzer MP, et al. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood. 2011 Nov 3; 118(18):4985–91. doi: 10.1182/blood-2011-07-364190 PMID: 21876119

12. Green NS, Barral S. Emerging science of hydroxyurea therapy for pediatric sickle cell disease. Pediatr Res. 2014 Jan; 75(1–2):196–204.

13. Rodgers GP, Dover GJ, Noguchi CT, Schechter AN, Nienhuis AW. Hematologic Responses of Patients with Sickle Cell Disease to Treatment with Hydroxyurea. N Engl J Med. 1990; 322(15):1037–45. PMID: 1690857

14. Pecoraro A, Rigano P, Troia A, Calzolari R, Scazzone C, Maggio A, et al. Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta-thalassemia. Eur J Haematol. 2014 Sep; 92(1):66–72. doi: 10.1111/ejh.12204 PMID: 24112139

15. Musallam KM, Taher AT, Cappellini MD, Sankaran VG. Clinical Experience with Fetal Hemoglobin Induction Therapy in Patients with β -thalassemia. Blood. 2013; 121(12):2199–220. doi: 10.1182/blood-2012-10-408021 PMID: 23315167

16. Ghatpande SS, Choudhary PK, Quinn CT, Goodman SR. In vivo pharmaco-proteomic analysis of hydroxyurea induced changes in the sickle red blood cell membrane proteome. J Proteomics. Elsevier B. V.; 2010 Jan 3; 73(3):619–26.

17. Costa FC, da Cunha AF, Fattori A, de Sousa Peres T, Costa GGL, Machado TF, et al. Gene expression profiles of erythroid precursors characterise several mechanisms of the action of hydroxycarbamide in sickle cell anemia. Br J Haematol. 2007 Jan; 136(2):333–42. PMID: 17156400

18. Flanagan JM, Steward S, Howard T a, Mortier N a, Kimble AC, Aygun B, et al. Hydroxycarbamide alters erythroid gene expression in children with sickle cell anemia. Br J Haematol. 2012 Apr; 157(2):240–8. doi: 10.1111/j.1365-2457.2012.09061.x PMID: 22360576

19. Pourfarzad F, von Lindern M, Azarkeivan A, Hou J, Kia SK, Esteghamat F, et al. Hydroxyurea responsiveness in β-thalassemic patients is determined by the stress response adaptation of erythroid progenitors and their differentiation propensity. Haematologica. 2013 May; 98(5):696–704. doi: 10.3324/haematol.2012.074492 PMID: 23100274

20. Lee M, Kwon J, Kim SN, Kim JE, Koh WS, Kim E-J, et al. cDNA microarray gene expression profiling of hydroxyurea, paclitaxel, and p-anisidine, genotoxic compounds with differing tumorigenicity results. Environ Mol Mutagen. 2003 Jan; 42(2):91–7. PMID: 12929121

21. Lettre G, Sankaran VG, Bezerra MA, Araujo AS, Uda M, Sanna S, et al. DNA polymorphisms at the BCL11A, HBS1L-MYB, and β -globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. PNAS. 2008; 105(33):11869–74. doi: 10.1073/pnas.0804799105 PMID: 18667998

22. Sedgewick AE, Timofeev N, Sebastiani P, So JCC, Ma ESK, Chan LC, et al. BCL11A is a major HbF quantitative trait locus in three different populations with beta-hemoglobinopathies. Blood Cells Mol Dis. 2008; 41(3):255–8. doi: 10.1016/j.bcmd.2008.06.007 PMID: 18691915

23. Menzel S, Garner C, Gut I, Matsuda F, Yamaguchi M, Heath S, et al. A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15. Nat Genet. 2007 Oct; 39(10):1197–9. PMID: 17767159

24. Sankaran VG, Menne TF, Xu J, Akie TE, Lettre G, Handel B Van, et al. Human Fetal Hemoglobin Expression Is Regulated by the Developmental Stage-Specific Repressor BCL11A. Science (80-). 2008; 322:1839–42.

25. Sankaran VG. Targeted therapeutic strategies for fetal hemoglobin induction. Hematology Am Soc Hematol Educ Program. 2011 Jan; 2011:459–65. doi: 10.1182/asheducation-2011.1.459 PMID: 22160074

26. Xu J, Sankaran VG, Ni M, Menne TF, Puram R V, Kim W, et al. Transcriptional silencing of (gamma)-globin by BCL11A involves long-range interactions and cooperation with SOX6. Genes Dev. 2010 Apr 15; 24(8):783–98. doi: 10.1101/gad.1897310 PMID: 20395365

27. Zhou D, Liu K, Sun C-W, Pawlik KM, Townes TM. KLF1 regulates BCL11A expression and gamma-to beta-globin gene switching. Nat Genet. Nature Publishing Group; 2010 Sep; 42(9):742–4. doi: 10.1038/ng.637 PMID: 20676097

28. Nuez B, Michalovich D, Bygrave A, Ploemacher R, Grosveld F. Defective haematopoiesis in fetal liver resulting from inactivation of the EKLF gene. Nature. 1995; 375(25):316–8.

29. Perkins AC, Sharpe AH, Orkin SH. Lethal beta-thalassaemia in mice lacking the erythroid CACCC transcription factor EKLF. Nature. 1995; 375:318–22. PMID: 7753195

30. Drissen R, Palstra R, Gillemans N, Splinter E, Grosveld F, Philipsen S, et al. The active spatial organization of the β- globin locus requires the transcription factor EKLF. Genes Dev. 2004; 18:2485–90. PMID: 15489291
31. Borg J, Papadopoulos P, Georgitsi M, Gutiérrez L, Grech G, Fanis P, et al. Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin. Nat Publ Gr. Nature Publishing Group; 2010; 42(9):813–7.

32. Wadman IA, Osada H, Grutz GG, Agulnick AD, Westphal H, Forster A, et al. The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1 / NLI proteins. EMBO J. 1997; 16(11):3145–57. PMID: 9214632

33. Soler E, Andrieu-Soler C, de Boer E, Bryne JC, Thongjuea S, Stadhouders R, et al. The genome-wide dynamics of the binding of Ldb1 complexes during erythroid differentiation. Genes Dev. 2010 Feb 1; 24(3):277–89. doi: 10.1101/gad.551810 PMID: 20123907

34. Song S-H, Hou C, Dean A. A positive role for NLI/Ldb1 in long-range beta-globin locus control region function. Mol Cell. 2007 Dec 14; 28(5):810–22. PMID: 18082606

35. Li L, Lee JY, Gross J, Song S-H, Dean A, Love PE. A requirement for Lim domain binding protein 1 in erythropoiesis. J Exp Med. 2010 Nov 22; 207(12):2543–50. doi: 10.1084/jem.20100504 PMID: 21041453

36. Elntsiki L, Miller W, Hardison R. Conserved E Boxes Function as Part of the Enhancer in Hypersensitive Site 2 of the β-globin Locus Control Region. ROLE OF BASIC HELIX-LOOP-HELIX PROTEINS. J Biol Chem. 1997 Jan 3; 272(1):369–78. PMID: 8995271

37. Holmes ML, Haeley JD, Cerruti L, Zhou W, Zogos H, Smith DE, et al. Identification of Id2 as a Globin Regulatory Protein by Representational Difference Analysis of K562 Cells Induced To Express gamma-Globin with a Fungal Compound. Mol Cell Biol. 1999; 19(6):4182–90. PMID: 10330158

38. Boyer SH, Belding TK, Margolet L, Noyes AN. Fetal Hemoglobin Restriction to a Few Erythrocytes (F Cells) in Normal Human Adults. Science (80). 1975; 188:361–3.

39. Wood W, Stamatoyannopoulos G. F-cells in the Adult: Normal Values and Levels in Individuals with Hereditary and Acquired Elevations of HbF. Blood. 1975; 46(5):671–83. PMID: 1100141

40. Papayannopoulou T, Brice M, Stamatoyannopoulos G. Hemoglobin F synthesis in vitro: Evidence for control at the level of primitive erythroid stem cells. PNAS. 1977; 74(7):2923–7. PMID: 286643

41. Moore KA, Ema H, Lemischka IR. In vitro maintenance of highly purified, transplantable hematopoietic stem cells. Blood. 1997 Jun 15; 89(12):4337–47. PMID: 9192358

42. Manz MG, Miyamoto T, Akashi K, Weissman IL. Prospective isolation of human clonogenic common myeloid progenitors. Proc Natl Acad Sci U S A. 2002 Sep 3; 99(18):11872–7. PMID: 12193648

43. Olivier EN, Qiu C, Velho M, Hirsch RE, Bouhassira EE. Large-scale production of embryonic red blood cells from human embryonic stem cells. Exp Hematol. 2006 Dec; 34(12):1635–42. PMID: 17157159

44. Qiu C, Olivier EN, Velho M, Bouhassira EE. Globin switches in yolk sac-like primitive and fetal-like definitive red blood cells produced from human embryonic stem cells. Blood. 2008 Mar 15; 111(4):2400–8. PMID: 18024790

45. Spandidos A, Wang X, Wang H, Seed B. PrimerBank: A resource of human and mouse PCR primer pairs for gene expression detection and quantification. Nucleic Acids Res. 2010; 38:D792–9. doi: 10.1093/nar/gkp1005 PMID: 19906719

46. Lavelle D, Vaitkus K, Ruiz MA, Ibanez K, Bouhassira EE, et al. Effect of AGM and fetal liver-derived stromal cell lines on globin expression in adult baboon (P. anubis) bone marrow-derived erythroid progenitors. PLOS One. 2012 Jan; 7(5):e36846. doi:10.1371/journal.pone.0036846

47. Macklis RM, Javid J, Lipton JM, Kudisch M, Pettis PK, Nathan DG. Synthesis of Hemoglobin F in Adult Simian Erythroid Progenitor-derived Colonies. J Clin Invest. 1982; 70(October):752–61.

48. Bauer DE, Kamran SC, Lessard S, Xu J, Fujiwara Y, Lin C, et al. An Erythroid Enhancer of BCL11A Subjugates γ-globin Expression to Genetic Variation Determines Fetal Hemoglobin Level. Science. 2013 Oct 11; 342(6155):253–7. doi: 10.1126/science.1242088 PMID: 2411543

49. Bianchi E, Zini R, Salati S, Tenedini E, Norfo R, Tagliafico E, et al. c-myc supports erythropoiesis through the transactivation of KLF1 and LMO2 expression. Blood. 2010 Nov 25; 116(22):e99–110. doi: 10.1182/blood-2009-08-238311 PMID: 20968118

50. Suzuki M, Yamauchi H, Mukai HY, Motohashi H, Shen Z, Tanabe O, et al. Disruption of the Hbs1l-Myb locus causes hereditary persistence of fetal hemoglobin in a mouse model. Mol Cell Biol. 2013 Apr; 33(8):1667–75. doi: 10.1128/MCB.01617-12 PMID: 23429969

51. Farrell JJ, Sherva RM, Chen Z, Luo H, Chu BF, Ha SY, et al. A 3-bp deletion in the HBS1L-MYB intergenic region on chromosome 6q23 is associated with HbF expression. Blood. 2011; 117(18):4935–46. doi: 10.1182/blood-2010-11-317081 PMID: 21389556